Risk Factors for Renal Impairment in Adult Patients With Short Bowel Syndrome

Peng Wang, Jianbo Yang, Yupeng Zhang, Li Zhang, Xuejin Gao, Xinying Wang, Peng Wang, Jianbo Yang, Yupeng Zhang, Li Zhang, Xuejin Gao, Xinying Wang

Abstract

Renal impairment is a common complication in patients with intestinal failure that is mostly caused by short bowel syndrome (SBS) and is associated with adverse outcomes that severely affect the quality of life or even survival. The prevalence and risk factors for renal impairment in patients with SBS remain unclarified. Therefore, we aimed to determine the prevalence of renal impairment and identify potential risk factors for renal impairment in adult patients with SBS. We retrospectively identified 199 patients diagnosed with SBS admitted to the Department of General Surgery between January 1, 2012 and January 1, 2019, from a prospectively maintained database. Overall, 56 patients (28.1%) with decreased renal function (eGFR < 90 mL/min/1.73 m2). The median duration of SBS was 7 months (IQR, 3-31 months) and the mean eGFR was 103.1 ± 39.4 mL/min/1.73 m2. Logistic regression modeling indicated that older age [odds ratio (OR), 1.074; 95% CI, 1.037-1.112, P < 0.001], kidney stones (OR, 4.887; 95% CI, 1.753-13.626; P = 0.002), decreased length of the small intestine (OR, 0.988; 95% CI, 0.979-0.998; P = 0.019), and prolonged duration of SBS (OR, 1.007; 95% CI, 1.001-1.013; P = 0.046) were significant risk factors for renal impairment. This is the largest study that has specifically explored the risk factors for renal impairment in a large cohort of adults with SBS. The present study showed that renal function should be closely monitored during treatment, and patients should be given prophylactic interventions if necessary. This retrospective study is a part of clinical study NCT03277014, registered in ClinicalTrials.gov PRS. And the PRS URL is http://register.clinicaltrials.gov.

Keywords: intestinal failure; renal impairment; risk factors; selective digestive decontamination; short bowel syndrome.

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2021 Wang, Yang, Zhang, Zhang, Gao and Wang.

Figures

Figure 1
Figure 1
The flow chart demonstrates the selection process of the patients.

References

    1. Pironi L, Arends J, Bozzetti F, Cuerda C, Gillanders L, Jeppesen PB, et al. ESPEN guidelines on chronic intestinal failure in adults. Clin Nutr. (2016) 35:247–307. 10.1016/j.clnu.2016.01.020
    1. Boncompain-Gerard M, Robert D, Fouque D, Hadj-Aissa A. Renal function and urinary excretion of electrolytes in patients receiving cyclic parenteral nutrition. JPEN J Parenter Enteral Nutr. (2000) 24:234–9. 10.1177/0148607100024004234
    1. Buchman AL, Moukarzel A, Ament ME, Gornbein J, Goodson B, Carlson C, et al. . Serious renal impairment is associated with long-term parenteral nutrition. JPEN J Parent Enteral Nutr. (1993) 17:438–44. 10.1177/0148607193017005438
    1. Lauverjat M, Hadj Aissa A, Vanhems P, Bouletreau P, Fouque D, Chambrier C. Chronic dehydration may impair renal function in patients with chronic intestinal failure on long-term parenteral nutrition. Clin Nutr. (2006) 25:75–81. 10.1016/j.clnu.2005.09.010
    1. Pironi L, Lauro A, Soverini V, Zanfi C, Agostini F, Guidetti M, et al. . Renal function in patients on long-term home parenteral nutrition and in intestinal transplant recipients. Nutrition. (2014) 30:1011–4. 10.1016/j.nut.2014.02.001
    1. Lysaght MJ. Maintenance dialysis population dynamics: current trends and long-term implications. J Am Soc Nephrol. (2002) 13(Suppl. 1):S37–40.
    1. Bailie GR, Uhlig K, Levey AS. Clinical practice guidelines in nephrology: evaluation, classification, and stratification of chronic kidney disease. Pharmacotherapy. (2005) 25:491–502. 10.1592/phco.25.4.491.61034
    1. Meguid El Nahas A, Bello AK. Chronic kidney disease: the global challenge. Lancet. (2005) 365:331–40. 10.1016/s0140-6736(05)17789-7
    1. Schwartz GJ, Work DF. Measurement and estimation of GFR in children and adolescents. Clin J Am Soc Nephrol. (2009) 4:1832–43. 10.2215/cjn.01640309
    1. Hsu CY, Bansal N. Measured GFR as “gold standard” —all that glitters is not gold? Clin J Am Soc Nephrol. (2011) 6:1813–4. 10.2215/cjn.06040611
    1. Ylinen E, Merras-Salmio L, Gunnar R, Jahnukainen T, Pakarinen MP. Intestinal failure as a significant risk factor for renal impairment in children. Nutrition. (2018) 45:90–3. 10.1016/j.nut.2017.07.011
    1. Dibaise JK, Young RJ, Vanderhoof JA. Enteric microbial flora, bacterial overgrowth, and short-bowel syndrome. Clin Gastroenterol Hepatol. (2006) 4:11–20. 10.1016/j.cgh.2005.10.020
    1. Joly F, Mayeur C, Bruneau A, Noordine ML, Meylheuc T, Langella P, et al. . Drastic changes in fecal and mucosa-associated microbiota in adult patients with short bowel syndrome. Biochimie. (2010) 92:753–61. 10.1016/j.biochi.2010.02.015
    1. Ranganathan N, Friedman EA, Tam P, Rao V, Ranganathan P, Dheer R. Probiotic dietary supplementation in patients with stage 3 and 4 chronic kidney disease: a 6-month pilot scale trial in Canada. Curr Med Res Opin. (2009) 25:1919-30. 10.1185/03007990903069249
    1. Crespo-Salgado J, Vehaskari VM, Stewart T, Ferris M, Zhang Q, Wang G, et al. . Intestinal microbiota in pediatric patients with end stage renal disease: a Midwest Pediatric Nephrology Consortium study. Microbiome. (2016) 4:50. 10.1186/s40168-016-0195-9
    1. Wang F, Jiang H, Shi K, Ren Y, Zhang P, Cheng S. Gut bacterial translocation is associated with microinflammation in end-stage renal disease patients. Nephrology. (2012) 17:733–8. 10.1111/j.1440-1797.2012.01647.x
    1. Lauritano EC, Gabrielli M, Scarpellini E, Ojetti V, Roccarina D, Villita A, et al. . Antibiotic therapy in small intestinal bacterial overgrowth: rifaximin versus metronidazole. Eur Rev Med Pharmacol Sci. (2009) 13:111–6.
    1. Esposito I, de Leone A, Di Gregorio G, Giaquinto S, de Magistris L, Ferrieri A, et al. . Breath test for differential diagnosis between small intestinal bacterial overgrowth and irritable bowel disease: an observation on non-absorbable antibiotics. World J Gastroenterol. (2007) 13:6016–21. 10.3748/wjg.v13.45.6016
    1. Madrid AM, Hurtado C, Venegas M, Cumsille F, Defilippi C. Long-Term treatment with cisapride and antibiotics in liver cirrhosis: effect on small intestinal motility, bacterial overgrowth, and liver function. Ame J Gastroenterol. (2001) 96:1251–5. 10.1111/j.1572-0241.2001.03636.x
    1. Kondrup J, Allison SP, Elia M, Vellas B, Plauth M. ESPEN guidelines for nutrition screening 2002. Clin Nutr. (2003) 22:415–21. 10.1016/s0261-5614(03)00098-0
    1. Detsky AS, McLaughlin JR, Baker JP, Johnston N, Whittaker S, Mendelson RA, et al. What is subjective global assessment of nutritional status? J Parent Enteral Nutr. (1987) 11:8–13. 10.1177/014860718701100108
    1. Cederholm T, Bosaeus I, Barazzoni R, Bauer J, Van Gossum A, Klek S, et al. . Diagnostic criteria for malnutrition—an ESPEN Consensus Statement. Clini Nutr. (2015) 34:335–40. 10.1016/j.clnu.2015.03.001
    1. Inker LA, Schmid CH, Tighiouart H, Eckfeldt JH, Feldman HI, Greene T, et al. . Estimating glomerular filtration rate from serum creatinine and cystatin C. New Engl J Med. (2012) 367:20–9. 10.1056/NEJMoa1114248
    1. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF, III, Feldman HI, et al. . A new equation to estimate glomerular filtration rate. Ann Intern Med. (2009) 150:604–12. 10.7326/0003-4819-150-9-200905050-00006
    1. Inker LA, Astor BC, Fox CH, Isakova T, Lash JP, Peralta CA, et al. . KDOQI US commentary on the 2012 KDIGO clinical practice guideline for the evaluation and management of CKD. Am J Kidney Di. (2014) 63:713–35. 10.1053/j.ajkd.2014.01.416
    1. Khoshini R, Dai SC, Lezcano S, Pimentel M. A systematic review of diagnostic tests for small intestinal bacterial overgrowth. Digest Dis Sci. (2008) 53:1443–54. 10.1007/s10620-007-0065-1
    1. Ghoshal UC, Ghoshal U, Das K, Misra A. Utility of hydrogen breath tests in diagnosis of small intestinal bacterial overgrowth in malabsorption syndrome and its relationship with oro-cecal transit time. Indian J Gastroenterol. (2006) 25:6–10.
    1. Lin HC. Small intestinal bacterial overgrowth: a framework for understanding irritable bowel syndrome. Jama. (2004) 292:852–8. 10.1001/jama.292.7.852
    1. King CE, Toskes PP. Comparison of the 1-gram [14C]xylose, 10-gram lactulose-H2, and 80-gram glucose-H2 breath tests in patients with small intestine bacterial overgrowth. Gastroenterology. (1986) 91:1447–51. 10.1016/0016-5085(86)90199-x
    1. Bauer TM, Schwacha H, Steinbruckner B, Brinkmann FE, Ditzen AK, Kist M, et al. . Diagnosis of small intestinal bacterial overgrowth in patients with cirrhosis of the liver: poor performance of the glucose breath hydrogen test. J Hepatol. (2000) 33:382–6. 10.1016/s0168-8278(00)80273-1
    1. Ponziani FR, Gerardi V, Gasbarrini A. Diagnosis and treatment of small intestinal bacterial overgrowth. Expert Rev Gastroenterol Hepatol. (2016) 10:215–27. 10.1586/17474124.2016.1110017
    1. Husebye E. The pathogenesis of gastrointestinal bacterial overgrowth. Chemotherapy. (2005) 51(Suppl. 1):1–22. 10.1159/000081988
    1. Dukowicz AC, Lacy BE, Levine GM. Small intestinal bacterial overgrowth: a comprehensive review. Gastroenterol Hepatol. (2007) 3:112–22.
    1. Wanitschke R, Ammon HV. Effects of dihydroxy bile acids and hydroxy fatty acids on the absorption of oleic acid in the human jejunum. J Clin Invest. (1978) 61:178–86. 10.1172/jci108916
    1. Grace E, Shaw C, Whelan K, Andreyev HJ. Review article: small intestinal bacterial overgrowth—prevalence, clinical features, current and developing diagnostic tests, and treatment. Aliment Pharmacol Ther. (2013) 38:674–88. 10.1111/apt.12456
    1. Agostini F, Sasdelli AS, Guidetti M, Comai G, La Manna G, Pironi L. Outcome of kidney function in adults on long-term home parenteral nutrition for chronic intestinal failure. Nutrition. (2019) 60:212–6. 10.1016/j.nut.2018.10.005
    1. Pironi, Loris . Definitions of intestinal failure and the short bowel syndrome. Best Pract Res Clin Gastroenterol. (2016) 30:173–85. 10.1016/j.bpg.2016.02.011
    1. Johnson E, Vu L, Matarese LE. Bacteria, bones, and stones: managing complications of short bowel syndrome. Nutr Clin Pract. (2018) 33:454–66. 10.1002/ncp.10113
    1. Khan SR, Pearle MS, Robertson WG, Gambaro G, Canales BK, Doizi S, et al. . Kidney stones. Nat Rev Dis Primers. (2016) 2:16008. 10.1038/nrdp.2016.8
    1. O'Connor RC, Worcester EM, Evan AP, Meehan S, Kuznetsov D, Laven B, et al. . Nephrolithiasis and nephrocalcinosis in rats with small bowel resection. Urol Res. (2005) 33:105–15. 10.1007/s00240-004-0460-4
    1. McConnell N, Campbell S, Gillanders I, Rolton H, Danesh B. Risk factors for developing renal stones in inflammatory bowel disease. BJU Int. (2002) 89:835–41. 10.1046/j.1464-410x.2002.02739.x
    1. Clarke AM, McKenzie RG. Ileostomy and the risk of urinary uric acid stones. Lancet. (1969) 2:395–7. 10.1016/s0140-6736(69)90108-1
    1. Li CC, Chien TM, Wu WJ, Huang CN, Chou YH. Uric acid stones increase the risk of chronic kidney disease. Urolithiasis. (2018) 46:543–7. 10.1007/s00240-018-1050-1
    1. Yang J, Sun H, Wan S, Mamtawla G, Gao X, Zhang L, et al. . Risk factors for nephrolithiasis in adults with short bowel syndrome. Ann Nutr Metab. (2019) 75:47–54. 10.1159/000502329
    1. Hofmann AF, Poley JR. Role of bile acid malabsorption in pathogenesis of diarrhea and steatorrhea in patients with ileal resection. I. response to cholestyramine or replacement of dietary long chain triglyceride by medium chain triglyceride. Gastroenterology. (1972) 62:918–34.
    1. Perinpam M, Enders FT, Mara KC, Vaughan LE, Mehta RA, Voskoboev N, et al. . Plasma oxalate in relation to eGFR in patients with primary hyperoxaluria, enteric hyperoxaluria and urinary stone disease. Clin Biochem. (2017) 50:1014–9. 10.1016/j.clinbiochem.2017.07.017
    1. Stoutenbeek CP, van Saene HK, Miranda DR, Zandstra DF. The effect of selective decontamination of the digestive tract on colonisation and infection rate in multiple trauma patients. Intensive Care Med. (1984) 10:185–92. 10.1007/bf00259435
    1. Price R, MacLennan G, Glen J. Selective digestive or oropharyngeal decontamination and topical oropharyngeal chlorhexidine for prevention of death in general intensive care: systematic review and network meta-analysis. BMJ. (2014) 348:g2197. 10.1136/bmj.g2197
    1. Duggan CP, Jaksic T. Pediatric intestinal failure. N Engl J Med. (2017) 377:666–75. 10.1056/NEJMra1602650
    1. Vaziri ND, Wong J, Pahl M, Piceno YM, Yuan J, DeSantis TZ, et al. . Chronic kidney disease alters intestinal microbial flora. Kidney Int. (2013) 83:308–15. 10.1038/ki.2012.345

Source: PubMed

Sponsorit ja yhteistyökumppanit

Sairaudet

Huumeiden interventiot

3
Tilaa